Clinical efficacy of Shirishavaleha on Tamaka Bronchial Asthma

Pharmaceutical development of Shirishavaleha and its Granules prepared with Khanda Sharkara and their comparative efficacy on Tamaka Shwasa (Bronchial Asthma) - SHA SHG

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2016/03/006695

Enrollment

Registered

2016-03-02

Start date

Unknown

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients having classical signs and symptoms of Tamaka Shwasa (Bronchial Asthma)

Interventions

Intervention1: Shirishavaleha: 10 g twice with luke warm water Orally for 28 Days Control Intervention1: Shirishavaleha Granules: 10 g twice with luke warm water orally for 28 days

Eligibility

Inclusion criteria

Inclusion criteria: Mild persistent cases of Bronchial Asthma withdaytime symptoms 3-6/week and nocturnal symptoms with 3-4/month. Moderate persistence cases with daytime symptoms daily and nocturnal symptoms with one or more than one week but not more than 2 weeks.

Exclusion criteria

Exclusion criteria: Known patients of diabetes, Dyspnoea resulting from cardiac origin, anaemia, Age above 60 years and below 20 years, Patients suffering from tuberculosis, malignancy and other chronic debilitating diseases, HIV positive cases, Pregnant and lactating mothers Patients who depend on regular use of inhalers, Patients suffering with other types of Shwasa explained in AYurveda classics like i.e. Maha, Urdha, Chhinna Shwasa will be excluded from the study.

Design outcomes

Primary

Measure	Time frame
It is expected that the trial drugs will exert a significant action on Signs and Symptoms of Tamaka Shwasa. Improvement in AEC and other haematological (TLC, DLC, Hb, AEC), Peak Expiratory Flow Rate and Breath Holding Time.Timepoint: A special scoring pattern will be followed for assessing improvement in signs and symptoms Routine urine and haematological investigations will be carried out to exclude other pathology Special investigations BHT and PEFR will be carried out for before and after treatment for assessment	—

Measure

Time frame

It is expected that the trial drugs will exert a significant action on Signs and Symptoms of Tamaka Shwasa. Improvement in AEC and other haematological (TLC, DLC, Hb, AEC), Peak Expiratory Flow Rate and Breath Holding Time.Timepoint: A special scoring pattern will be followed for assessing improvement in signs and symptoms Routine urine and haematological investigations will be carried out to exclude other pathology Special investigations BHT and PEFR will be carried out for before and after treatment for assessment

—

Secondary

Measure	Time frame
By providing better effect on Tamaka Shwasa, the drug will effect psychosomatic level of the enrolled patients, enhance quality of life and will contribute in reducing disability adjusted life years. Overall improvement in the disease condition, Quality of Life of the diseased. Based on the observations, the trial drug may be recommended to be added into the Essential Drugs List of Ministry of AYUSH, New DelhiTimepoint: 18 months of trial	—

Measure

Time frame

By providing better effect on Tamaka Shwasa, the drug will effect psychosomatic level of the enrolled patients, enhance quality of life and will contribute in reducing disability adjusted life years. Overall improvement in the disease condition, Quality of Life of the diseased. Based on the observations, the trial drug may be recommended to be added into the Essential Drugs List of Ministry of AYUSH, New DelhiTimepoint: 18 months of trial

—

Countries

India

Contacts

Public ContactDr Galib

IPGTRA

galib14@yahoo.co.in9428671275

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026